{
    "nct_id": "NCT03460067",
    "official_title": "Selective Use of Observation After Lumpectomy and Sentinel Lymph Node Biopsy in Her-2 Positive Patients With Pathologic Complete Response to Neoadjuvant Chemotherapy",
    "inclusion_criteria": "* Ability to understand and the willingness to sign a written informed consent.\n* Karnofsky Performance Status 50% to 100% (Appendix A).\n* Women 40 years of age or older with a diagnosis of invasive ductal carcinoma\n* Her-2 3+ or FISH ratio of 2.2 or higher, background gene expression with normal copy number\n* Only postmenopausal women will be eligible. Subjects will be classified as being postmenopausal if they have had:\n\n  * No spontaneous menses > 1 year, or\n  * Bilateral surgical oophorectomy, or\n  * No menses for < 1 year with FSH and estradiol levels in according to institutional standards\n* cT1-2N0 on clinical staging (verified to have no suspicious axillary or internal mammary nodes on MRI or ultrasound)\n* Undergo neoadjuvant chemotherapy with a trastuzumab based regimen prior to surgery and plan for completion of one year of trastuzumab\n* Patients are required to undergo lumpectomy with sentinel lymph node biopsy\n* Pathologic review shows no evidence of residual disease in the tumor bed (to also include no evidence of residual DCIS)\n* Tumor bed should be no larger than 5 cm in size on pathologic review\n* Fibrotic area of prior tumor located at least 3 mm away from surgical margins\n* No evidence of treatment related change in the lymph nodes on pathologic review\n\nExclusion Criteria\n\n* Diagnosis of inflammatory breast cancer\n* Previously diagnosed malignancy excluding basal or squamous cell carcinoma of the skin (unless disease-free for 5 years or more)\n* Diagnosis of metastatic disease\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 40 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}